A randomized open-label trial of on-demand rabeprazole<i>vs</i>ranitidine for patients with non-erosive reflux disease

Kobeissy, Abdallah; Hashash, Jana G.; Jamali, Faek; Skoury, Assaad; Haddad, Reham; El-Samad, Sarah; Ladki, Rami; Aswad, Rola; Soweid, Assaad

doi:10.3748/wjg.v18.i19.2390

Cited by 7 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Correlatively with the literature, in the present study, on-demand treatment with H 2 RA led to a decrease in the complaints of retrosternal burning sensation, regurgitation, nausea, vomiting, and burping. In a study comparing rabeprazole and ranitidine treatments, no significant difference was found between two groups in terms of symptom relief, amount of medication received, and the number of days without medication (23). In the present study, although there was a decrease in the severity of all compliants of GERD in both study groups, only a statistically significant decrease was observed in the H 2 RA group.…”

Section: Discussioncontrasting

confidence: 79%

Comparison of the Efficacies of Proton Pump Inhibitors and H2 Receptor Antagonists in on-Demand Treatment of Gastroesophageal Reflux Disease

Vardı¹,

Köroğlu²,

Tüzün³

et al. 2018

Anatol J FM

View full text Add to dashboard Cite

Objective: On-demand treatment protocols in the maintenance treatment of gastroesophageal reflux disease (GERD) are cost-efficient and easy-to-use treatments.This study aimed to compare the efficacies of H2 receptor antagonists (H 2 RA) and proton pump inhibitors (PPI) in on-demand treatment of GERD. Methods:Patients with persistent GERD symptoms were enrolledbetween January-November 2015 and were randomly separated into two equal groups. The patients in the first group were commenced on ranitidine 300 mg as H2RA and the patients in the second group were commenced on pantoprazole 40 mg. A 4-point Likert-type scale generated by the researchers was applied to evaluate the frequencies of reflux symptoms and their impacts on activities of life and business life.Results: Fifty-two patients were included, of whom 26 (50.0%) were in the PPI group and 26 (50.0%) were in the H 2 RA group. There were no significant differences between the study groups both before and after treatment in terms of the severity of reflux symptoms. There were significant decreases in the H2RA group in terms of the domains of retrosternal burning sensation, regurgitation, nausea and vomiting, and burping (p=0.036, p=0.027, p=0.020, and p=0.038, respectively). Conclusion:PPIs and H2RAs were both effective in maintaining symptom control and improving the limitations in work or activities in on-demand treatment.Nonetheless, the higher amount of the medication use in the H2RA group compared with the PPI group led us to conclude that using PPIs during on-demand treatment might be more appropriate than using H2RA in this setting.

show abstract

Section: Discussioncontrasting

confidence: 79%

Comparison of the Efficacies of Proton Pump Inhibitors and H2 Receptor Antagonists in on-Demand Treatment of Gastroesophageal Reflux Disease

Vardı¹,

Köroğlu²,

Tüzün³

et al. 2018

Anatol J FM

View full text Add to dashboard Cite

show abstract

“…However, the use of pharmacological agents comes with the concern of tolerability141516, defined as discontinuation caused for any reason, including ineffectiveness, adverse effects and a lack of compliance. There is substantial evidence for the effectiveness and tolerability of pharmacological agents in the treatment of GERD141718192021. However, most of these findings have been obtained from pairwise comparisons within each class of drugs.…”

mentioning

confidence: 99%

Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Meta-Analysis and GRADE system

Chao

Kwong

Yuan

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) are used for gastro-esophageal reflux disease (GERD); however, the clinical evidence for treatment is poor. We evaluated the effectiveness and tolerability of different doses of PPIs, H2RAs and placebo in adults with GERD. Six online databases were searched through September 1, 2016. All related articles were included and combined with a Bayesian network meta-analysis from randomized controlled trials (RCTs). The GRADE systems were employed to assess the main outcome. Ninety-eight RCTs were identified, which included 45,964 participants. Our analysis indicated that the full/standard dose of esomeprazole at 40 mg per day was the most efficient in healing among nine different dosages of PPIs and H2RAs. The main efficacy outcome did not change after adjustments for the area, age, level of disease from endoscopy, year of publication, pharmaceutical industry sponsorship, Intention-to-treat (ITT)/per-protocol (PP), withdrawal rate, pre-set select design bias, single blinded and unblinded studies, study origination in China, study arms that included zero events, inconsistency node or discontinued drug were accounted for in the meta-regressions and sensitivity analyses. This research suggests that the full/standard doses (40 mg per day) of esomeprazole should be recommended as first-line treatments for GERD in adults for short-term therapy.

show abstract

“…One recently published study revealed similar efficacy and degree of improvement in the quality of life assessed with the SF-36 questionnaire in a group of NERD patients given ranitidine or rabeprazole on demand [37].…”

Section: Influence Of Pharmacotherapy On the Quality Of Lifementioning

confidence: 72%

Quality of life in patients with gastroesophageal reflux disease following pharmacotherapeutic, endoscopic, and surgical treatment

Jurkowska

Świdnicka-Siergiejko

Łagoda

et al. 2016

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is associated with bothersome symptoms. Their chronic and recurrent character has a negative impact on the physical and mental status of the patients. Improvement in health-related quality of life (HRQOL) of GERD patients along with decreasing the severity of symptoms remain the main aims of therapy. This paper reviews literature regarding HRQOL in GERD patients, as well as the impact of various treatment modalities on the patient's status, the incidence and severity of symptoms thereof, and subjective quality of life. Additionally, the factors that may influence the treatment outcome are also discussed. Several studies showed that the improvement of HRQOL is greater after surgical treatment than with pharmacological therapy. However, long-term studies are still needed to determine if surgery can constitute the equivalent of lifelong medical therapy. StreszczenieChoroba refluksowa przełyku (GERD) wiąże się z występowaniem uciążliwych objawów. Ich przewlekły i powtarzający się charakter negatywnie wpływa na stan fizyczny i psychiczny pacjentów. Poprawa jakości życia związanej ze zdrowiem (HRQOL) pacjentów z GERD oraz zmniejszenie nasilenia objawów są głównymi celami terapii. W pracy dokonano przeglą-du piśmiennictwa dotyczącego HRQOL u pacjentów z GERD, wpływu różnych metod leczenia na stan pacjentów, częstości występowania objawów i ich nasilenia oraz subiektywnej jakości ich życia. Dodatkowo omówiono czynniki, które mogą mieć wpływ na wyniki terapii. Wyniki wielu badań wykazały, że poprawa HRQOL jest większa po zabiegu chirurgicznym w porównaniu z terapią farmakologiczną. Nadal jednak potrzebne są długoterminowe badania, aby ustalić, czy zabieg chirurgiczny może stanowić odpowiednik terapii farmakologicznej.

show abstract

A randomized open-label trial of on-demand rabeprazolevsranitidine for patients with non-erosive reflux disease

Abstract: Rabeprazole has a comparable efficacy compared to ranitidine when given on-demand for the treatment of NERD. Both medications were associated with improved quality of life.

Cited by 7 publications

References 28 publications

Comparison of the Efficacies of Proton Pump Inhibitors and H2 Receptor Antagonists in on-Demand Treatment of Gastroesophageal Reflux Disease

Comparison of the Efficacies of Proton Pump Inhibitors and H2 Receptor Antagonists in on-Demand Treatment of Gastroesophageal Reflux Disease

Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Meta-Analysis and GRADE system

Quality of life in patients with gastroesophageal reflux disease following pharmacotherapeutic, endoscopic, and surgical treatment

Contact Info

Product

Resources

About